 |
Case Report
Nivolumab induced tenosynovitis which resolved without the use of steroids
1 Fellow, Hematology/Oncology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA
2 Attending Physician, Hematology/Oncology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA
Address correspondence to:
Eugen A Shippey
1118 Nolan Street, San Antonio, TX 78202,
USA
Message to Corresponding Author
Article ID: 100090Z10ES2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Shippey E, Setlik R. Nivolumab induced tenosynovitis which resolved without the use of steroids. J Case Rep Images Oncology 2021;7:100090Z10ES2021.ABSTRACT
Introduction: The advent of immunotherapy with PDL1 inhibitors like nivolumab has dramatically altered the oncology treatment armamentarium for advanced stage cancer and offers the possibility of long-term survival for some patients. However, these agents are associated with autoimmune adverse effects, some of which are still being characterized.
Case Report: Our case demonstrates reversible autoimmune tenosynovitis attributable to nivolumab. There have been four prior cases of autoimmune tenosynovitis associated with nivolumab use described in the literature. This is the first case described in which symptoms resolved rapidly without the use of steroids. Treatment was successfully restarted and tolerated for an additional year without further significant side effects.
Conclusion: This case is important because it demonstrates that some patients developing immune checkpoint inhibitor (ICI)-induced autoimmune tenosynovitis may continue cancer therapy with an ICI without concurrent immunosuppression and toxicities of systemic steroids.
Keywords: Autoimmune tenosynovitis, Checkpoint inhibitors, Immune-related adverse events, Melanoma, Nivolumab
SUPPORTING INFORMATION
Author Contributions
Eugen A Shippey - Substantial contributions to conception and design, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Robert Setlik - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Eugen Shippey et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
